Coughing; Didn't eat anything until 5; Severe flu; was very sick on Saturday; Diagnosed with Covid-19; Lack of efficacy; Severe flu symptoms; Dry heaving; Completely wiped out the whole day; The patient confirmed with the technician that he received the half dose; This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 01-Nov-2021. The most recent information was received on 03-Nov-2021 and was forwarded to Moderna on 03-Nov-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Severe flu symptoms), RETCHING (Dry heaving), COUGH (Coughing), FEEDING DISORDER (Didn't eat anything until 5) and INFLUENZA (Severe flu) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012F21A and 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR) for an unknown indication.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INCORRECT DOSE ADMINISTERED (The patient confirmed with the technician that he received the half dose). On 30-Oct-2021, the patient experienced INFLUENZA LIKE ILLNESS (Severe flu symptoms), RETCHING (Dry heaving) and FATIGUE (Completely wiped out the whole day). On 02-Nov-2021, the patient experienced COVID-19 (Diagnosed with Covid-19). 02-Nov-2021, the patient experienced DRUG INEFFECTIVE (Lack of efficacy). On an unknown date, the patient experienced COUGH (Coughing), FEEDING DISORDER (Didn't eat anything until 5), INFLUENZA (Severe flu) and ILLNESS (was very sick on Saturday). The patient was treated with IBUPROFEN on 30-Oct-2021 for Adverse event, at an unspecified dose and frequency. On 29-Oct-2021, INCORRECT DOSE ADMINISTERED (The patient confirmed with the technician that he received the half dose) had resolved. On 02-Nov-2021, DRUG INEFFECTIVE (Lack of efficacy) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Severe flu symptoms), RETCHING (Dry heaving), FEEDING DISORDER (Didn't eat anything until 5), INFLUENZA (Severe flu), COVID-19 (Diagnosed with Covid-19), ILLNESS (was very sick on Saturday) and FATIGUE (Completely wiped out the whole day) outcome was unknown and COUGH (Coughing) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Nov-2021, COVID-19: Diagnosed with Covid-19.         The patient states that he had no side effects from the first two doses.   The patient states that abated at 6 o'clock at night. On 31-Oct-2021, it was better but not as good. On 01-Nov-2021 he was now halfway back to normal. He states it surprised him because it was like a severe flu. He still had coughing and continuing today. It was less frequent today.   Most recent FOLLOW-UP information incorporated above includes: On 03-Nov-2021: signi follow-up included lab details added; Sender's Comments: This case of incorrect dose administered concerns a 65-year-old, male patient with no medical history reported, who experienced the unexpected non-serious adverse event of special interest of COVID-19 and other non-serious unexpected events. Drug ineffective was considered as and additional event. The event of COVID-19 occurred approximately 4 days after the third dose of Moderna COVID-19 vaccine. The rechallenge was not applicable since the event occurred after the last dose. The benefit-risk relationship of Moderna COVID-19 vaccine is not affected by this report. The patient mentioned that he received the half of the dose but is not specified if correct dose for booster (0.25 ml) was administered.